A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well differentiated metastatic pancreatic neuroendocrine tumors

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515045-42-00

Enrollment

Registered

2024-10-11

Start date

2018-04-23

Completion date

2025-06-06

Last updated

2024-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive well-differentiated metastatic neuroendocrine tumors of the pancreas

Brief summary

Disease control rate (DCR) after 6 months from study entry, determined according to RECIST 1.1 or death

Detailed description

- Objective tumor response (ORR) - progression-free survival (PFS) - overall survival (OS) - toxicity - biochemical response (tumor marker chromogranin A; in cases of functional NET: gastrin, insulin) - Quality of Life (EORTC QLQ-C30 questionnaire) Translational research: - Predictive biomarkers (circulating VEGF, ANGPT1/2 and IL8 levels, immunohistochemical VEGFR2 expression)

Interventions

DRUGCyramza 10 mg/ml concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease control rate (DCR) after 6 months from study entry, determined according to RECIST 1.1 or death	—

Secondary

Measure	Time frame
- Objective tumor response (ORR) - progression-free survival (PFS) - overall survival (OS) - toxicity - biochemical response (tumor marker chromogranin A; in cases of functional NET: gastrin, insulin) - Quality of Life (EORTC QLQ-C30 questionnaire) Translational research: - Predictive biomarkers (circulating VEGF, ANGPT1/2 and IL8 levels, immunohistochemical VEGFR2 expression)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026